rotation.to
Following this device: dark.
Free account
rotation.to
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Cognex Corporation

CGNX · Nasdaq

Health CareLife-science toolsJust dropped outAIRobotics

CGNX stood above a rising 150-day average in 41 of the last 52 weekly readings, and has been out of that trend for the last 1 week. It is 11.0% below that average now. Life Science Tools & Research Services: 52% of its 79 stocks in an uptrend (+4 points in four weeks); Health Care: 25% (−11 points in four weeks).

Statistics

Rotation
Just dropped out
Weeks in an uptrend
out for 1
Industry in uptrend
52% +4 in 4 wk
Insider buys, 12 months
$0
Insider sales, 12 months
$69.9M
Officials’ trades on record
40
Institutions holding
612 (+84)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 41 of 52 weeks.

17 Apr – 16 Oct
26%41%57%Apr 26Jun 26Jul 26Sep 26Oct 26

Life-science tools: About half its stocks are in an uptrend and the share has been climbing. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$30.5M$0Nov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

40 disclosed lines: House 37, Senate 3, executive 0; 9 people.

WhoDidAmountTraded
Donald S. Beyer, Jr. House: U.S. House ClerkVA08sold$1k–$15k28 Feb 2022filed 3 Mar 2022
Donald S. Beyer, Jr. House: U.S. House ClerkVA08sold$1k–$15k17 Sep 2021filed 1 Oct 2021
Donald S. Beyer, Jr. House: U.S. House ClerkVA08bought$1k–$15k3 Dec 2020filed 1 Jan 2021
Donald S. Beyer, Jr. House: U.S. House ClerkVA08bought$1k–$15k17 Nov 2020filed 1 Dec 2020
Greg Gianforte House: U.S. House ClerkMT00sold$1k–$15k13 Oct 2020filed 9 Nov 2020
Donald S. Beyer, Jr. House: U.S. House ClerkVA08soldjoint$1k–$15k14 Jul 2020filed 9 Aug 2020
Donald S. Beyer, Jr. House: U.S. House ClerkVA08sold$1k–$15k7 May 2020filed 31 May 2020
Donald S. Beyer, Jr. House: U.S. House ClerkVA08soldjoint$1k–$15k1 May 2020filed 31 May 2020
Donald S. Beyer, Jr. House: U.S. House ClerkVA08soldjoint$1k–$15k28 Apr 2020filed 9 May 2020
Sheldon Whitehouse Senate: U.S. Senate eFDSenatorsold$15k–$50k11 Mar 2020filed 14 Apr 2020
Donald S. Beyer, Jr. House: U.S. House ClerkVA08boughtjoint$1k–$15k14 Feb 2020filed 22 Feb 2020
Donald S. Beyer, Jr. House: U.S. House ClerkVA08boughtjoint$1k–$15k28 Jan 2020filed 22 Feb 2020

Insiders

Buy orders, 12 months0
Sale orders, 12 months14
Buyers · sellers0 · 9
WhoDidSharesTraded
Matthew MoschnerCEO & Presidentsold1,600at $65.3611 Aug 2026filed 12 Aug 2026
Matthew MoschnerCEO & Presidentsold4,000at $65.3611 Aug 2026filed 12 Aug 2026
Matthew MoschnerCEO & Presidentsold4,000at $63.6211 Aug 2026filed 12 Aug 2026
Matthew MoschnerCEO & Presidentsold7,000at $63.6111 Aug 2026filed 12 Aug 2026
Matthew MoschnerCEO & Presidentsold8,362at $63.6211 Aug 2026filed 12 Aug 2026
Darren Marc LongVice Presidentsold4,500at $66.3227 May 2026filed 28 May 2026
Darren Marc LongVice Presidentsold8,675at $66.3227 May 2026filed 28 May 2026
Darren Marc LongVice Presidentsold5,498at $66.3227 May 2026filed 28 May 2026
Darren Marc LongVice Presidentsold1,579at $66.5227 May 2026filed 28 May 2026
Laura Ann MacdonaldVP and PAOsold6,100at $65.5612 May 2026filed 12 May 2026
Laura Ann MacdonaldVP and PAOsold10,000at $65.5612 May 2026filed 12 May 2026
Laura Ann MacdonaldVP and PAOsold25,500at $65.5612 May 2026filed 12 May 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders612+84 on the quarter
New · exited138 · 58
Reported value$11.9B

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
BlackRock, Inc.reduced · filed 7 Aug 202615,991,755$1.2B-250,340−1.5%
VANGUARD PORTFOLIO MANAGEMENT LLCreduced · filed 13 Aug 202610,099,866$731.4M-270,781−2.6%
Invesco Ltd.added · filed 14 Aug 20268,206,627$594.3M+5,219,751+174.8%
VANGUARD CAPITAL MANAGEMENT LLCadded · filed 13 Aug 20267,509,391$543.8M+79,235+1.1%
Pictet Asset Management Holding SAreduced · filed 30 Jul 20265,829,878$422.0M-843,153−12.6%
NORDEA INVESTMENT MANAGEMENT ABreduced · filed 5 Aug 20265,820,165$407.4M-321,453−5.2%
STATE STREET CORPadded · filed 7 Aug 20265,419,280$392.5M+157,780+3.0%
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 20264,918,798$356.3M+220,056+4.7%
DISCIPLINED GROWTH INVESTORS INCreduced · filed 14 Aug 20264,139,715$299.8M-182,360−4.2%
ARROWSTREET CAPITAL, LIMITED PARTNERSHIPadded · filed 13 Aug 20262,979,759$215.8M+946,668+46.6%
31 Mar 2023 – 30 Jun 2026
377490603Mar 23Dec 23Dec 24Sep 25Jun 26

Everyone who traded it

Matthew Moschner Company insiderCEO & President · last 11 Aug 20260 · 1
Darren Marc Long Company insiderVice President · last 7 Aug 20260 · 1
Laura Ann Macdonald Company insiderVP and PAO · last 12 May 20260 · 6
Mark Fennell Company insiderChief Legal Officer &Secretary · last 11 May 20260 · 1
Dennis Fehr Company insiderSVP, Chief Financial Officer · last 6 May 20261 · 0
Dianne M. Parrotte Company insiderDirector · last 2 Mar 20263 · 11
Angelos Papadimitriou Company insiderDirector · last 23 Feb 20260 · 1
Carl Gerst Company insiderEVP, Global Sales and Products · last 23 Feb 20260 · 6
Anthony Sun Company insiderDirector · last 21 Feb 20260 · 13
Joerg Kuechen Company insiderHead of Corporate M&A · last 21 Feb 20260 · 4
John Tseng-Chung Lee Company insiderDirector · last 21 Feb 20260 · 0
Marjorie Sennett Company insiderDirector · last 21 Feb 20260 · 0

Same industry

OABI OmniAbLeading+65%
TXG 10x GenomicsLeading+60%
AVTR AvantorLeading+47%
ILMN IlluminaLeading+44%
RVTY RevvityLeading+37%
MASS 908 DevicesLeading+31%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202566.9%
Operating profit marginFY 2025 · to 31 Dec 202516.3%
Free cash flow marginFY 2025 · to 31 Dec 202523.8%
Return on capital employedFY 2025 · to 31 Dec 20258.9%
Cash conversionFY 2025 · to 31 Dec 2025215%
Research spendFY 2025 · to 31 Dec 202514.0%
Dividend growthFY 2025 · to 31 Dec 2025306%
Share count trendFY 2025 · to 1 Feb 2026-0.8%
Cash and equivalentsFY 2025 · to 31 Dec 2025$262.9M
Free cash flowFY 2025 · to 31 Dec 2025$236.8M

Analyst forecasts

No analyst forecasts yet.